Latest news with #AcrivonTherapeutics
Yahoo
3 days ago
- Business
- Yahoo
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types New paradigm for accelerated design and development of novel compounds, like ACR-2316, based on optimal intracellular pathway selectivity, uniquely enabled by AI-driven AP3 Generative Phosphoproteomics platform Cash, cash equivalents and marketable securities of $147.6 million as of June 30, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ('Acrivon' or 'Acrivon Therapeutics') (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today reported financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. 'The strength of the clinical data across our two clinical assets speaks to the expanding capabilities of our AP3 platform to enable pathway-based drug design and optimized drug development by delivering actionable insights,' said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. 'With ACR-368, we have seen deep and durable responses in patients with various types of aggressive endometrial cancer who had all progressed on prior chemotherapy and anti-PD1 therapy – a high unmet need population. Based on our clinical data, and the AP3-discovered insight that ultra low-dose gemcitabine sensitizes tumors to ACR-368 treatment, we believe there is an opportunity to further expand the patient population benefiting from ACR-368 by treating all-comer, biomarker-unselected 2nd line patients, who have all received prior chemotherapy and anti-PD-1, with ACR-368 and ultra low-dose gemcitabine. Our fully internally developed second clinical-stage asset, ACR-2316, which is being advanced in a Phase 1 trial, has demonstrated initial clinical activity during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer, signaling the broad potential of this agent.' Recent Highlights ACR-368: CHK1 and CHK2 Inhibitor Continued advancement of the ongoing registrational-intent, multicenter Phase 2b trial of ACR-368 in patients with recurrent high-grade endometrial cancer who have all received prior platinum-based chemotherapy and prior immune checkpoint inhibitor treatment regimens Initiated a third arm to the Phase 2b study without the need for a pre-treatment biopsy to evaluate ACR-368 with ultra low-dose gemcitabine (ULDG) as a tumor sensitizer in all-comer, biomarker-unselected 2nd line patients with endometrial cancer who have all received prior treatment with chemotherapy and anti-PD-1 ACR-2316: WEE1/PKMYT1 Inhibitor Continued enrolling patients in the Phase 1 monotherapy dose-escalation trial for certain high unmet need solid tumor types prioritized based on AP3-predicted sensitivity to ACR-2316 No dose-limiting toxicities observed in three cleared dose levels Evidence of drug target engagement observed as early as dose level 1 Initial clinical activity observed during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer Generative Phosphoproteomics AP3 Platform At the AACR Annual Meeting in April 2025, presented Generative Phosphoproteomic AP3 analyses uncovering key molecular mechanisms by which ACR-2316 induces strong mitotic, pro-apoptotic tumor cell death believed to be critical for its potent, preclinical single-agent activity Anticipated Upcoming Milestones Provide update on registrational-intent trial and confirmatory trial design for ACR-368 in the second half of 2025 Report initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025 Advance a new potential first-in-class cell cycle drug discovery program for an undisclosed target towards development candidate nomination in 2025 Second Quarter 2025 Financial Results Net loss for the quarter ended June 30, 2025 was $21.0 million compared to a net loss of $18.8 million for the same period in 2024. Research and development expenses were $16.2 million for the quarter ended June 30, 2025 compared to $15.0 million for the same period in 2024. The difference was primarily due to increased personnel to support the continued execution of the clinical trials for ACR-368 and ACR-2316, as well as preclinical drug discovery advancement. General and administrative expenses were $6.5 million for the quarter ended June 30, 2025, which is materially consistent with $6.4 million for the same period in 2024. As of June 30, 2025, the company had cash, cash equivalents and investments of $147.6 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027. About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development. Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company's second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company's clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. In addition, the company is advancing a preclinical program directed against an undisclosed cell cycle regulatory target. Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled 'Risk Factors' in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law. Investor and Media Contacts: Adam D. Levy, Ph.D., Alexandra Santos asantos@ Acrivon Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited, in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 16,182 $ 15,025 $ 31,596 $ 26,498 General and administrative 6,467 6,412 12,715 12,607 Total operating expenses 22,649 21,437 44,311 39,105 Loss from operations (22,649 ) (21,437 ) (44,311 ) (39,105 ) Other income (expense), net: Interest income 1,730 2,694 3,726 4,140 Other expense, net (87 ) (55 ) (101 ) (319 ) Total other income, net 1,643 2,639 3,625 3,821 Net loss $ (21,006 ) $ (18,798 ) $ (40,686 ) $ (35,284 ) Net loss per share - basic and diluted $ (0.55 ) $ (0.52 ) $ (1.06 ) $ (1.20 ) Weighted-average common stock outstanding - basic and diluted 38,461,619 36,132,616 38,406,339 29,361,710 Comprehensive loss: Net loss $ (21,006 ) $ (18,798 ) $ (40,686 ) $ (35,284 ) Other comprehensive income (loss): Unrealized (loss) gain on available-for-sale investments, net of tax (177 ) 51 (341 ) 64 Comprehensive loss $ (21,183 ) $ (18,747 ) $ (41,027 ) $ (35,220 ) Acrivon Therapeutics, Inc. Condensed Consolidated Balance Sheets (unaudited, in thousands) June 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 41,895 $ 39,818 Investments 105,727 144,751 Other assets 10,961 12,019 Total assets $ 158,583 $ 196,588 Liabilities and Stockholders' Equity Liabilities $ 15,546 $ 19,802 Stockholders' Equity 143,037 176,786 Total Liabilities and Stockholders' Equity $ 158,583 $ 196,588 Sign in to access your portfolio
Yahoo
17-05-2025
- Business
- Yahoo
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to re-validate the company's tumor-selection platform, the analyst tells investors in a research note. The firm prefers to wait for initial data from ACR-2316 in the second half of 2025 and more meaningful data in 2026 before recommending the shares. Jones would like to see some 'real de-risking clinical data to comfortably' value Acrivon's biomarker-based selection platform. Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ACRV: Disclaimer & DisclosureReport an Issue Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating Acrivon Therapeutics Reports Q1 2025 Progress and Financials Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
15-05-2025
- Business
- Business Insider
Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer
Oppenheimer lowered the firm's price target on Acrivon Therapeutics (ACRV) to $9 from $10 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company's Q1 results and updates on its cash and share position, the analyst tells investors in a research note. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
14-05-2025
- Business
- Yahoo
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose escalation cohorts completed in ACR-2316 Phase 1 trial with tumor shrinkage observed already at dose level (DL)3, below projected recommended Phase 2 dose AACR presentation of ACR-2316 revealing mechanisms underlying its superior preclinical activity with potent mitotic tumor cell death using AP3 Generative Phosphoproteomics Mansoor Raza Mirza, M.D. appointed chief medical officer; accomplished clinician with stellar track record of successfully leading registrational trials through regulatory approvals, and establishing new standards of care in gynecological oncology Cash, cash equivalents and marketable securities of $164.8 million as of March 31, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ('Acrivon' or 'Acrivon Therapeutics') (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision oncology medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today reported financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights. 'We made substantial progress in the first quarter in the advancement of our clinical pipeline and the expansion of our Generative Phosphoproteomics AP3 capabilities, as well as strengthening the executive team,' said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. 'At our corporate R&D event, we reported positive updated interim data from our ongoing ACR-368 Phase 2b study in endometrial cancer patients with large tumors and aggressive histopathologies – all of whom had progressed after prior platinum-based chemotherapy and anti-PD-1. With a significant unmet need for second-line treatment options and the potential for label expansion through a confirmatory trial in the front-line setting with ACR-368 used as switch maintenance, we remain very excited by the opportunities for this program. For our second clinical-stage asset, ACR-2316, we have observed tumor shrinkage (~25%) in a patient with significant metastatic solid tumor burden after only six weeks of treatment at dose level 3 - well before reaching our projected RP2D, supporting its potential for monotherapy activity. Finally, we are thrilled and feel privileged that Dr. Mansoor Raza Mirza, a globally recognized oncologist, is now leading the development of our pipeline as CMO. Mansoor has made significant contributions in clinical oncology as a lead investigator for multiple approved drugs and senior author of national cancer guidelines.' Recent Highlights Presented interim data (February 25, 2025) from the ongoing Phase 2b registrational-intent trial of ACR-368 in patients with heavily pretreated endometrial cancer who had all progressed on prior anti-PD-1 and chemotherapy Among the 20 OncoSignature-positive (BM+) patients, the confirmed overall response rate (cORR) was 35%, more than double that in the prior line of therapy, and the disease control rate (DCR) was 80% In the BM+ patients that had relapsed after the prior line of therapy, the cORR was 50%, mDOR was not yet reached (>10 months), and DCR was 100% In the BM+ patients with tumors refractory to last prior line of therapy, significant clinical activity was observed with a cORR of 33% and DCR of 75% Provided an overview of the expanded capabilities of the company's Generative Phosphoproteomics AP3 platform highlighting the growing suite of powerful, internally-developed tools, including the AP3 Data Portal, designed to convert multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor, and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development. Advanced to DL4 in the Phase 1 monotherapy clinical trial of ACR-2316, with encouraging observations at DLs 1-3: DL 1, 2, and 3 cleared without safety concerns or dose-limiting toxicities (DLTs) by the safety review committee, and DL4 is now enrolling Drug target engagement observed at DL1 and 2 using the company's clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses Notably, initial clinical activity of ~25% RECIST tumor shrinkage and a reduction of metastatic lesions throughout the chest, abdomen and pelvis was observed after six weeks of treatment in a patient at DL3 (below projected RP2D) who had received three prior lines of therapy including chemotherapy and anti-PD1 Presented at the AACR Annual Meeting Generative Phosphoproteomic AP3 analyses uncovering key molecular mechanisms by which ACR-2316 induces strong mitotic and replicative tumor cell death believed to be critical for its potent single-agent activity Appointed Mansoor Raza Mirza, M.D., as chief medical officer, bringing decades of experience as a distinguished and highly accomplished oncology key opinion leader with a stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology Promoted Adam D. Levy, Ph.D., M.B.A., to chief financial officer, having served as the company's head of investor relations and with prior finance and strategy leadership roles at Zentalis Pharmaceuticals, Turning Point Therapeutics, Novartis, Gilead, and McKinsey & Company Anticipated Upcoming Milestones Provide update on registrational-intent trial and confirmatory trial design for ACR-368 Report initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025 Advance a new potential first-in-class cell cycle drug discovery program for an undisclosed target towards development candidate nomination in 2025 First Quarter 2025 Financial Results Net loss for the quarter ended March 31, 2025 was $19.7 million compared to a net loss of $16.5 million for the same period in 2024. Research and development expenses were $15.4 million for the quarter ended March 31, 2025 compared to $11.5 million for the same period in 2024. The difference was primarily due to the continued execution of the clinical trials for ACR-368 and ACR-2316, as well as preclinical drug discovery advancement and increased personnel to support these research and development activities. General and administrative expenses were $6.2 million for the quarter ended March 31, 2025, which is materially consistent with the same period in 2024. As of March 31, 2025, the company had cash, cash equivalents and investments of $164.8 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027. About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development. Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company's second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company's clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. The company also has a preclinical cell cycle program with an undisclosed target. Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled 'Risk Factors' in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law. Investor and Media Contacts: Adam D. Levy, Ph.D., Alexandra Santos asantos@ Acrivon Therapeutics, Consolidated Statements of Operations and Comprehensive Loss(unaudited, in thousands, except share and per share data) Three Months Ended March 31, 2025 2024 Operating expenses: Research and development $ 15,414 $ 11,473 General and administrative $ 6,248 $ 6,195 Total operating expenses 21,662 17,668 Loss from operations (21,662 ) (17,668 ) Other income (expense), net: Interest income 1,996 1,446 Other expense, net (14 ) (264 ) Total other income, net 1,982 1,182 Net loss $ (19,680 ) $ (16,486 ) Net loss per share - basic and diluted $ (0.51 ) $ (0.73 ) Weighted-average common stock outstanding – basic and diluted 38,350,444 22,590,804 Comprehensive loss: Net loss $ (19,680 ) $ (16,486 ) Other comprehensive income (loss): Unrealized (loss) gain on available-for-sale investments, net of tax (164 ) 13 Comprehensive loss $ (19,844 ) $ (16,473 )Acrivon Therapeutics, Consolidated Balance Sheets(unaudited, in thousands) March 31, December 31, 2025 2024 Assets Cash and cash equivalents $ 39,154 $ 39,818 Investments 125,676 $ 144,751 Other assets 11,519 $ 12,019 Total assets $ 176,349 $ 196,588 Liabilities and Stockholders' Equity Liabilities 15,959 19,802 Stockholders' Equity 160,390 176,786 Total Liabilities and Stockholders' Equity $ 176,349 $ 196,588 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-04-2025
- Business
- Yahoo
April 2025's Standout Penny Stocks
The U.S. stock market recently experienced a significant rebound, with major indices like the Dow Jones surging over 1,000 points as investors reacted to a flurry of earnings reports and ongoing tariff discussions. In such a volatile market landscape, identifying potential in smaller or newer companies can be particularly rewarding. While "penny stocks" may sound outdated, they still represent opportunities within less-established firms that could offer substantial value when backed by strong financials and clear growth prospects. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.22 $345.99M ★★★★☆☆ Tuya (NYSE:TUYA) $1.89 $1.16B ★★★★★★ CI&T (NYSE:CINT) $4.99 $671.52M ★★★★★☆ Smith Micro Software (NasdaqCM:SMSI) $0.89 $16.25M ★★★★☆☆ Flexible Solutions International (NYSEAM:FSI) $3.74 $47.81M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.54 $74.62M ★★★★★★ BAB (OTCPK:BABB) $0.7902 $5.88M ★★★★★★ QuantaSing Group (NasdaqGM:QSG) $3.08 $218.76M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.79 $84.44M ★★★★★☆ New Horizon Aircraft (NasdaqCM:HOVR) $0.485 $14.05M ★★★★★★ Click here to see the full list of 789 stocks from our US Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing oncology medicines tailored to patients with tumors predicted to respond well, using its proteomics-based platform, and has a market cap of $56.75 million. Operations: Acrivon Therapeutics, Inc. has not reported any revenue segments as it is a clinical stage biopharmaceutical company. Market Cap: $56.75M Acrivon Therapeutics, a pre-revenue biopharmaceutical company with a market cap of US$56.75 million, is navigating the volatile landscape typical of penny stocks. Recent executive changes include the appointment of Dr. Mansoor Raza Mirza as Chief Medical Officer, bringing significant expertise in oncology to the team. The company remains debt-free and has sufficient short-term assets to cover liabilities, providing some financial stability despite ongoing losses and high share price volatility. Acrivon's recent FDA Breakthrough Device designation for its ACR-368 OncoSignature assay highlights potential growth avenues amidst competitive challenges in the biotech sector. Click to explore a detailed breakdown of our findings in Acrivon Therapeutics' financial health report. Review our growth performance report to gain insights into Acrivon Therapeutics' future. Simply Wall St Financial Health Rating: ★★★★★★ Overview: C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates to degrade disease-causing proteins, with a market cap of $88.74 million. Operations: C4 Therapeutics generates revenue from its Pharmaceuticals segment, totaling $35.58 million. Market Cap: $88.74M C4 Therapeutics, with a market cap of US$88.74 million, exemplifies the volatility and challenges often seen in penny stocks. The company remains unprofitable, with losses totaling US$105.32 million for 2024, although it has sufficient short-term assets to cover liabilities and is debt-free. Recent board changes include Bruce Downey's retirement announcement without any strategic disagreements. Despite a forecasted revenue growth of 58.87% annually, earnings are expected to decline by an average of 6.5% over the next three years, highlighting potential hurdles amid its clinical-stage developments in biopharmaceuticals. Navigate through the intricacies of C4 Therapeutics with our comprehensive balance sheet health report here. Gain insights into C4 Therapeutics' future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: SmartRent, Inc. is an enterprise real estate technology company offering management software and applications to rental property stakeholders globally, with a market cap of approximately $152.55 million. Operations: SmartRent's revenue is primarily derived from its Electronic Security Devices segment, which generated $174.89 million. Market Cap: $152.55M SmartRent, with a market cap of US$152.55 million, faces the typical volatility associated with penny stocks but offers some financial stability through its cash runway exceeding three years and no debt. Recent executive changes saw John Dorman appointed interim CEO following the departure of Michael Shane Paladin. Despite revenue declining to US$174.89 million in 2024 from the previous year, SmartRent's strategic innovations like Teams and Smart Launch aim to enhance operational efficiency in property management. However, persistent unprofitability and high share price volatility remain concerns for investors considering this stock category. Click here to discover the nuances of SmartRent with our detailed analytical financial health report. Examine SmartRent's earnings growth report to understand how analysts expect it to perform. Investigate our full lineup of 789 US Penny Stocks right here. Seeking Other Investments? Explore 21 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:ACRV NasdaqGS:CCCC and NYSE:SMRT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
